| __timestamp | Alnylam Pharmaceuticals, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 68205000 |
| Thursday, January 1, 2015 | 276495000 | 54218000 |
| Friday, January 1, 2016 | 382392000 | 15934000 |
| Sunday, January 1, 2017 | 390635000 | 24390000 |
| Monday, January 1, 2018 | 505420000 | 25389000 |
| Tuesday, January 1, 2019 | 655114000 | 72324000 |
| Wednesday, January 1, 2020 | 654819000 | 184809000 |
| Friday, January 1, 2021 | 792156000 | 205164000 |
| Saturday, January 1, 2022 | 883015000 | 245441000 |
| Sunday, January 1, 2023 | 1004415000 | 271823000 |
| Monday, January 1, 2024 | 1126232000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Alnylam Pharmaceuticals, Inc. and Madrigal Pharmaceuticals, Inc. have demonstrated contrasting strategies in this regard over the past decade. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, reflecting a robust focus on pioneering new treatments. In contrast, Madrigal's R&D spending, while increasing, grew at a more modest pace, approximately 300% during the same period.
Alnylam's aggressive investment strategy is evident, with its R&D expenses peaking at over $1 billion in 2023, a significant leap from $190 million in 2014. Meanwhile, Madrigal's R&D expenses reached $272 million in 2023, up from $68 million in 2014. This divergence highlights Alnylam's strategic emphasis on innovation, potentially positioning it as a leader in the pharmaceutical industry.
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and Madrigal Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc.
GSK plc vs Alnylam Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Grifols, S.A.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Research and Development Expenses Breakdown: Biogen Inc. vs Madrigal Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Dr. Reddy's Laboratories Limited and Madrigal Pharmaceuticals, Inc.
Analyzing R&D Budgets: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc